The Multiple Myeloma Channel is supported with funding from AbbVie (Platinum), Sanofi (Gold), Legend Biotech (Bronze), and through an educational grant from Alexion Pharma GmbH.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
iwMyeloma 2022 | Day 2 wrap-up: pushing myeloma boundaries
Gareth Morgan, MD, PhD, FRCP, FRCPath, of NYU Langone Medical Center, New York, NY chairs this session with Rafael Fonseca, MD, of Mayo Clinic, Phoenix, AZ, Leif Bergsagel, MD, of Mayo Clinic, Phoenix, AZ, and Keith Stewart, MB, ChB, of Princess Margaret Cancer Centre, Toronto, Canada. The experts discuss the biology behind the use of BCL2 inhibitors such as venetoclax, T-cell exhaustion as a key cause of resistance in many immunotherapies, protein-degrading drugs, and also how patient outcomes are likely to be improved in the coming years. This discussion took place at The International Workshop on Myeloma 2022, held in Scottsdale, AZ.
